Zymeworks Inc. (ZYME)
- Business Wire
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
VANCOUVER, British Columbia & SEATTLE, May 20, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its Board of Directors, after thorough consultation with its financial and legal advisors, unanimously determined that the unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons FZE ("All Blue"), and its affiliates to purchase Zymeworks for $10.50 per s
- PR Newswire
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.
All Blue Capital ("AB"), a global investment firm, today announced that Siddhartha Mukherjee, MD, Associate Professor of Medicine in the Division of Hematology/Oncology at Columbia University Medical Center in New York City, recently joined AB as Medical Advisor.
- Zacks
Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
